Cutaneous T Cell Lymphoma Therapeutics
1. Istodax patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US4977138 | BRISTOL-MYERS | FR901228 substance and preparation thereof |
Aug, 2013
(12 years ago) | |
| US7611724 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(4 years ago) | |
| US7608280 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2014 |
| Orphan Drug Exclusivity(ODE) | Jun 16, 2018 |
| Orphan Drug Exclusivity(ODE-12) | Jun 16, 2018 |
Drugs and Companies using ROMIDEPSIN ingredient
NCE-1 date: 05 November, 2013
Market Authorisation Date: 05 November, 2009
Dosage: POWDER
How can I launch a generic of ISTODAX before it's drug patent expiration?
More Information on Dosage
ISTODAX family patents
2. Targretin patent expiration
Treatment: Topical treatment of cutaneous lesions in patients with cutaneous t-cell lymphoma (stage ia and ib) who have refractory or persistent disease after other therapies or who have not tolerated other ther...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5780676 | BAUSCH | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
Jul, 2015
(10 years ago) | |
| US5962731 | BAUSCH | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
Oct, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-164) | Jul 29, 2018 |
Drugs and Companies using BEXAROTENE ingredient
Market Authorisation Date: 29 December, 1999
Dosage: CAPSULE; GEL
More Information on Dosage
TARGRETIN family patents
3. Zolinza patent
expiration
Treatment: Treatment of cutaneous manifestations in patients with cutaneous t-cell lymphoma (ctcl)
ZOLINZA's oppositions filed in EPO
Can you believe ZOLINZA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7456219 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2027
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE38506 | MSD SUB MERCK | Potent inducers of terminal differentiation and methods of use thereof |
Nov, 2013
(12 years ago) | |
| US8101663 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(2 years ago) | |
| US7652069 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(2 years ago) | |
| US7732490 | MSD SUB MERCK | Methods of treating cancer |
Mar, 2023
(2 years ago) | |
| US7399787 | MSD SUB MERCK | Methods of treating cancer with HDAC inhibitors |
Feb, 2025
(10 months ago) | |
| US8067472 | MSD SUB MERCK | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
Mar, 2023
(2 years ago) | |
| US7851509 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Feb, 2024
(1 year, 10 months ago) | |
| US8450372 | MSD SUB MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
Mar, 2028
(2 years from now) | |
| US8093295 | MSD SUB MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
May, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2011 |
| Orphan Drug Exclusivity(ODE) | Oct 06, 2013 |
Drugs and Companies using VORINOSTAT ingredient
NCE-1 date: 06 October, 2010
Market Authorisation Date: 06 October, 2006
Dosage: CAPSULE
More Information on Dosage
ZOLINZA family patents